Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Faron Pharmaceuticals garners some encouragement from phase III data; still searching for answers to key questions

It has discovered that a sub-group of patients with higher levels of certain bio-markers showed a reduced mortality rate and increased ventilator-free days
words clinical trial on a folder
Faron is trying to understand and explain a number of anomalies in the results

Faron Pharmaceuticals Ltd (LON:FARN) has made some important observations while assessing the data from its unsuccessful phase III trial of Traumakine for acute respiratory distress syndrome (ARDS).  

It has discovered that a sub-group of patients with higher levels of certain bio-markers (CD73 serum and MxA activation) showed a reduced mortality rate and increased ventilator-free days.

The results from this smaller cohort of 48 people mirrored those seen in the company's positive phase II study.

CLICK HERE: For the update in full 

But, as chief exeutive Dr Markku Jalkanen pointed out, while the feedback was encouraging it still did not explain many of the other results observed from the pivotal clinical assessment of the treatment.

Faron's team is still trying to understand why Traumakine activity was variable in the INTEREST trial compared to previous studies and why the mortality was so low in the group receiving the dummy placebo drug.

"This analysis will continue and we will keep our shareholders and the market informed with progress in due course," Jalkanen said.

 

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Newswire
September 12 2018

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use